£11.5M
ARCH Venture Partners led the oversubscribed round alongside participation from +ND Capital, OMX Ventures, and Meltwind.
Syndex Bio
Syndex Bio advances next-generation molecular diagnostics with its proprietary methyl-copying PCR platform.
£11.5MTotal raised
Syndex Bio is a biotechnology company developing proprietary molecular technologies to detect epigenetic alterations with unprecedented precision. The firm has introduced its methyl-copying PCR platform to improve molecular diagnostics.
Categories
Founders
GS
Geoff Smith
Founder and CEO